{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":5,"description":"Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nMetformin Hydrochloride: Given orally","id":"EG000","otherNumAffected":4,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Arm I (EBRT, Metformin Hydrochloride)"},{"deathsNumAffected":0,"deathsNumAtRisk":4,"description":"Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.\n\nExternal Beam Radiation Therapy: Undergo External Beam Radiation Therapy\n\nPlacebo: Given orally","id":"EG001","otherNumAffected":3,"otherNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"title":"Arm II (EBRT, Placebo)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Dry mouth","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":5},{"groupId":"EG001","numAffected":2,"numAtRisk":4}],"term":"Xerostomia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":5},{"groupId":"EG001","numAffected":2,"numAtRisk":4}],"term":"Dysphagia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":5},{"groupId":"EG001","numAffected":3,"numAtRisk":4}],"term":"Fatigue"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":5},{"groupId":"EG001","numAffected":3,"numAtRisk":4}],"term":"Dysgeusia"}],"timeFrame":"baseline through one year after completion of treatment"}